169 related articles for article (PubMed ID: 16202681)
1. Cytogenetic and molecular genetic abnormalities in agnogenic myeloid metaplasia.
Reilly JT
Semin Oncol; 2005 Aug; 32(4):359-64. PubMed ID: 16202681
[TBL] [Abstract][Full Text] [Related]
2. Cytogenetics of agnogenic myeloid metaplasia: a study of 61 patients.
Djordjevic V; Dencic-Fekete M; Jovanovic J; Bizic S; Jankovic G; Bogdanovic A; Cemerikic-Martinovic V; Gotic M
Cancer Genet Cytogenet; 2007 Feb; 173(1):57-62. PubMed ID: 17284371
[TBL] [Abstract][Full Text] [Related]
3. The impact of cytogenetic abnormalities on the prognosis of primary myelofibrosis: a prospective survey of 202 cases in Japan.
Hidaka T; Shide K; Shimoda H; Kameda T; Toyama K; Katayose K; Kubuki Y; Nagata K; Takenaka K; Akashi K; Okamura T; Niho Y; Mizoguchi H; Omine M; Ozawa K; Harada M; Shimoda K
Eur J Haematol; 2009 Oct; 83(4):328-33. PubMed ID: 19549278
[TBL] [Abstract][Full Text] [Related]
4. Cytogenetic and molecular genetic aspects of idiopathic myelofibrosis.
Reilly JT
Acta Haematol; 2002; 108(3):113-9. PubMed ID: 12373082
[TBL] [Abstract][Full Text] [Related]
5. [Cytogenetics and molecular genetics in myelofibrosis with myeloid metaplasia and polycythemia vera].
Roche-Lestienne C; Andrieux J
Pathol Biol (Paris); 2007 Feb; 55(1):49-55. PubMed ID: 16901657
[TBL] [Abstract][Full Text] [Related]
6. Presence of unfavorable cytogenetic abnormalities is the strongest predictor of poor survival in secondary myelofibrosis.
Dingli D; Schwager SM; Mesa RA; Li CY; Dewald GW; Tefferi A
Cancer; 2006 May; 106(9):1985-9. PubMed ID: 16568439
[TBL] [Abstract][Full Text] [Related]
7. Cytogenetic and molecular aspects of Philadelphia negative chronic myeloproliferative disorders: clinical implications.
Panani AD
Cancer Lett; 2007 Sep; 255(1):12-25. PubMed ID: 17383090
[TBL] [Abstract][Full Text] [Related]
8. Molecular characterization of permanent cell lines from primary, metastatic and recurrent malignant peripheral nerve sheath tumors (MPNST) with underlying neurofibromatosis-1.
Fang Y; Elahi A; Denley RC; Rao PH; Brennan MF; Jhanwar SC
Anticancer Res; 2009 Apr; 29(4):1255-62. PubMed ID: 19414372
[TBL] [Abstract][Full Text] [Related]
9. Prognostic relevance of cytogenetics determined by fluorescent in situ hybridization in patients having myelofibrosis with myeloid metaplasia.
Strasser-Weippl K; Steurer M; Kees M; Augustin F; Tzankov A; Dirnhofer S; Fiegl M; Simonitsch-Klupp I; Gisslinger H; Zojer N; Ludwig H
Cancer; 2006 Dec; 107(12):2801-6. PubMed ID: 17103442
[TBL] [Abstract][Full Text] [Related]
10. Gains on 9p are common genomic aberrations in idiopathic myelofibrosis: a comparative genomic hybridization study.
Al-Assar O; Ul-Hassan A; Brown R; Wilson GA; Hammond DW; Reilly JT
Br J Haematol; 2005 Apr; 129(1):66-71. PubMed ID: 15801957
[TBL] [Abstract][Full Text] [Related]
11. Myeloproliferative disorders.
Bench AJ; Cross NC; Huntly BJ; Nacheva EP; Green AR
Best Pract Res Clin Haematol; 2001 Sep; 14(3):531-51. PubMed ID: 11640868
[TBL] [Abstract][Full Text] [Related]
12. Karyotype and molecular cytogenetic studies in polycythemia vera.
Andrieux JL; Demory JL
Curr Hematol Rep; 2005 May; 4(3):224-9. PubMed ID: 15865876
[TBL] [Abstract][Full Text] [Related]
13. Prognostic diversity among cytogenetic abnormalities in myelofibrosis with myeloid metaplasia.
Tefferi A; Dingli D; Li CY; Dewald GW
Cancer; 2005 Oct; 104(8):1656-60. PubMed ID: 16104040
[TBL] [Abstract][Full Text] [Related]
14. Cytogenetic findings in untreated patients with essential thrombocythemia.
Panani AD
In Vivo; 2006; 20(3):381-4. PubMed ID: 16724675
[TBL] [Abstract][Full Text] [Related]
15. Detection of aberrant gene expression in CD34+ hematopoietic stem cells from patients with agnogenic myeloid metaplasia using oligonucleotide microarrays.
Jones LC; Tefferi A; Vuong PT; Desmond JC; Hofmann WK; Koeffler HP
Stem Cells; 2005 May; 23(5):631-7. PubMed ID: 15849170
[TBL] [Abstract][Full Text] [Related]
16. Cytogenetic studies and their prognostic significance in agnogenic myeloid metaplasia: a report on 47 cases.
Demory JL; Dupriez B; Fenaux P; Laï JL; Beuscart R; Jouet JP; Deminatti M; Bauters F
Blood; 1988 Sep; 72(3):855-9. PubMed ID: 3416075
[TBL] [Abstract][Full Text] [Related]
17. Long-term follow-up of a patient with idiopathic myelofibrosis associated with chromosome 11 and 13 abnormalities.
Toubai T; Tanaka J; Higa T; Ota S; Ibata M; Shono Y; Mashiko S; Miura Y; Umehara S; Kahata K; Toyoshima N; Morioka M; Asaka M; Kasai M; Imamura M
Am J Hematol; 2005 Jan; 78(1):67-70. PubMed ID: 15609290
[TBL] [Abstract][Full Text] [Related]
18. Conventional cytogenetics in myelofibrosis: literature review and discussion.
Hussein K; Van Dyke DL; Tefferi A
Eur J Haematol; 2009 May; 82(5):329-38. PubMed ID: 19141119
[TBL] [Abstract][Full Text] [Related]
19. Trisomy 13 in a case of myelofibrosis with myeloid metaplasia with early blastic transformation.
Ferrara F; Vicari L; Festa B; Di Noto R; Pane F; Sebastio L; Cimino R
Haematologica; 1995; 80(5):434-6. PubMed ID: 8566885
[TBL] [Abstract][Full Text] [Related]
20. Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia.
Tefferi A; Mesa RA; Schroeder G; Hanson CA; Li CY; Dewald GW
Br J Haematol; 2001 Jun; 113(3):763-71. PubMed ID: 11380468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
